Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853-6401.
Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853-6401.
J Dairy Sci. 2019 Nov;102(11):10316-10328. doi: 10.3168/jds.2019-16335. Epub 2019 Sep 5.
To evaluate the effect of recombinant bovine interleukin-8 (rbIL-8) on uterine health and milk production, 2 separate studies were conducted. For study 1, postpartum Holstein cows (n = 213) were randomly allocated into 1 of 3 intrauterine treatment groups: control (CTR, 250 mL of saline solution), low dose (L-IL8, 11.25 µg of rbIL-8 diluted in 250 mL of saline solution), and high dose (H-IL8, 1,125 µg of rbIL-8 diluted in 250 mL of saline solution). Intrauterine delivery of treatments was performed within 12 h of parturition. Cows were evaluated for retained fetal membranes, puerperal metritis, and clinical endometritis. Blood samples were collected immediately before treatment and 1, 2, and 3 d in milk for assessment of IL-8, haptoglobin, fatty acids, and β-hydroxybutyrate concentrations. Treatment with rbIL-8 reduced the incidence of puerperal metritis in multiparous cows (CTR = 34.3, L-IL8 = 8.11, and H-IL8 = 6.35%). Both the L-IL8 and H-IL8 groups produced significantly more milk, fat-corrected milk, and energy-corrected milk yields when compared with placebo-treated controls. A second study was performed to confirm the effect of rbIL-8 on milk production. In study 2, 164 primiparous cows were randomly allocated into 1 of 4 treatment groups: control (CTR, 250 mL of saline solution), low dose (L-IL8, 0.14 µg of rbIL-8), medium dose (M-IL8, 14 µg of rbIL-8), and high dose (H-IL8, 1,400 µg of rbIL-8). Treatments were prepared and administered as described for study 1. Cows in the L-IL8, M-IL8, and H-IL8 groups produced significantly more milk, fat-corrected milk, and energy-corrected milk yields when compared with control cows. In conclusion, treatment with rbIL-8 decreased the incidence of puerperal metritis in multiparous cows. The administration of rbIL-8 was repeatedly associated with a dramatic and long-lasting improvement of lactation performance.
为了评估重组牛白细胞介素-8(rbIL-8)对子宫健康和牛奶产量的影响，进行了两项独立的研究。在研究 1 中，将产后荷斯坦奶牛(213 头)随机分为 3 个子宫内治疗组之一：对照组(CTR，250 mL 生理盐水)、低剂量(L-IL8，用 250 mL 生理盐水稀释的 11.25 µg rbIL-8)和高剂量(H-IL8，用 250 mL 生理盐水稀释的 1,125 µg rbIL-8)。在分娩后 12 小时内进行子宫内给药。评估奶牛的胎衣滞留、产褥期子宫内膜炎和临床子宫内膜炎。在治疗前、治疗后 1、2 和 3 天采集血液样本，评估白细胞介素-8、触珠蛋白、脂肪酸和β-羟丁酸浓度。rbIL-8 治疗降低了经产奶牛的产褥期子宫内膜炎发生率(CTR=34.3%，L-IL8=8.11%，H-IL8=6.35%)。与安慰剂对照组相比，L-IL8 和 H-IL8 组的牛奶、校正脂肪奶和校正能量奶产量均显著增加。进行了第二项研究以确认 rbIL-8 对牛奶产量的影响。在研究 2 中，将 164 头初产奶牛随机分为 4 个治疗组之一：对照组(CTR，250 mL 生理盐水)、低剂量(L-IL8，0.14 µg rbIL-8)、中剂量(M-IL8，14 µg rbIL-8)和高剂量(H-IL8，1,400 µg rbIL-8)。治疗方法与研究 1 中描述的方法相同。与对照组奶牛相比，L-IL8、M-IL8 和 H-IL8 组的牛奶、校正脂肪奶和校正能量奶产量均显著增加。总之，rbIL-8 治疗降低了经产奶牛的产褥期子宫内膜炎发生率。rbIL-8 的给药与泌乳性能的显著且持久改善反复相关。
